Review



cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)  (STATA Corporation)


Bioz Verified Symbol STATA Corporation is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STATA Corporation cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazards Modeling With Stabilized Inverse Probability Of Treatment Weighting (Iptw), supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cox+proportional+hazards+modeling+with+stabilized+inverse+probability+of+treatment+weighting+%28iptw%29/pmc12163663-25-13-29?v=STATA+Corporation
    Average 90 stars, based on 1 article reviews
    cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw) - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer"

    Article Title: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

    Journal: JAMA Network Open

    doi: 10.1001/jamanetworkopen.2025.15087

    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.
    Figure Legend Snippet: Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

    Techniques Used: Generated



    Similar Products

    cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)  (STATA Corporation)
    90
    STATA Corporation cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw)
    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor <t>receptor</t> <t>(EGFR)</t> therapy. <t>IPTW</t> indicates stabilized inverse probability of treatment weights.
    Cox Proportional Hazards Modeling With Stabilized Inverse Probability Of Treatment Weighting (Iptw), supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cox+proportional+hazards+modeling+with+stabilized+inverse+probability+of+treatment+weighting+%28iptw%29/pmc12163663-25-13-29?v=STATA+Corporation
    Average 90 stars, based on 1 article reviews
    cox proportional hazards modeling with stabilized inverse probability of treatment weighting (iptw) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

    Journal: JAMA Network Open

    Article Title: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer

    doi: 10.1001/jamanetworkopen.2025.15087

    Figure Lengend Snippet: Estimated survival functions were generated independently for each of 25 imputations, with the mean subsequently calculated at each time interval to generate the estimated survival function after multiple imputation. Because the plot represents means of estimated survival functions and not directly observed data, the number at risk at each time are not provided. Estimated median survival was 15.6 months (95% CI, 12.5-17.1 months) in unadjusted and 15.3 months (95% CI, 12.5-17.1 months) in adjusted analysis for patients treated with anti–vascular endothelial growth factor (VEGF) therapy and 12.0 months (95% CI, 9.8-15.3 months) in unadjusted and 12.1 months (95% CI, 10.5-15.3 months) in adjusted analysis for patients treated with anti–epidermal growth factor receptor (EGFR) therapy. IPTW indicates stabilized inverse probability of treatment weights.

    Article Snippet: After MICE, we used Cox proportional hazards modeling with stabilized inverse probability of treatment weighting (IPTW) to assess the adjusted association of anti-EGFR vs anti-VEGF–containing treatment with OS using Stata/SE statistical software version 18.5 (StataCorp) (eMethods, eFigure 1, and eFigure 2 in ).

    Techniques: Generated